

IN THE CLAIMS

The status of the claims is provided below:

Claims 1-54: (Canceled).

55. (New) A medication for treating cancer and viral infections, comprising activated lymphocytes produced by activating lymphocytes with anti-CD3 antibody and/or IL-2 and inducing heat shock proteins in the lymphocytes.

56. (New) The medication of Claim 55, wherein the induced heat shock proteins have a molecular weight of 60 kDa to 80 kDa.

57. (New) The medication of Claim 55, wherein said induced heat shock proteins has a molecular weight of 70 kDa.

58. (New) The medication of Claim 55, wherein the heat shock proteins are induced by heating the activated lymphocytes.

59. (New) The medication of Claim 56, wherein the heat shock proteins are induced by heating the activated lymphocytes.

60. (New) The medication of Claim 57, wherein the heat shock proteins are induced by heating said activated lymphocytes.

61. (New) The medication of Claim 58, further comprising *Rauwolfia serpentine* in an amount sufficient to enhance the effect of the activated lymphocytes.

62. (New) The medication of Claim 58, further comprising reserpine in an amount sufficient to enhance the effect of the activated lymphocytes.

63. (New) The medication of Claim 59, further comprising *Rauwolfia serpentine* in an amount sufficient to enhance the effect of the activated lymphocytes.

64. (New) The medication of Claim 59, further comprising reserpine in an amount sufficient to enhance the effect of the activated lymphocytes.

65. (New) The medication of Claim 60, further comprising *Rauwolfia serpentine* in an amount sufficient to enhance the effect of the activated lymphocytes.

66. (New) The medication of Claim 60, further comprising reserpine in an amount sufficient to enhance the effect of the activated lymphocytes.

67. (New) The medication of Claim 58, wherein the lymphocytes are heated at a temperature of 38°C to 50°C to induce the heat shock proteins.

68. (New) The medication of Claim 59, wherein the lymphocytes are heated at a temperature of 38°C to 50°C to induce the heat shock proteins.

69. (New) The medication of Claim 60, wherein the lymphocytes are heated at a temperature of 38°C to 50°C to induce the heat shock proteins.

70. (New) The medication of Claim 58, wherein the lymphocytes are heated at a temperature of 38°C to 50°C for 5 seconds to 6 hours to induce the heat shock proteins.

71. (New) The medication of Claim 59, wherein the lymphocytes are heated at a temperature of 38°C to 50°C for 5 seconds to 6 hours to induce the heat shock proteins.

72. (New) The medication of Claim 60, wherein the lymphocytes are heated at a temperature of 38°C to 50°C for 5 seconds to 6 hours to induce the heat shock proteins.

73. (New) The medication of Claim 58, wherein the lymphocytes are heated at a temperature of 42°C to 45°C to induce the heat shock proteins.

74. (New) The medication of Claim 59, wherein the lymphocytes are heated at a temperature of 42°C to 45°C to induce the heat shock proteins

75. (New) The medication of Claim 60, wherein the lymphocytes are heated at a temperature of 42°C to 45°C to induce the heat shock proteins.

76. (New) The medication of Claim 58, wherein the lymphocytes are heated at a temperature of 42°C to 45°C for 10 minutes to 60 minutes to induce the heat shock proteins.

77. (New) The medication of Claim 59, wherein the lymphocytes are heated at a temperature of 42°C to 45°C for 10 minutes to 60 minutes to induce the heat shock proteins.

78. (New) The medication of Claim 60, wherein the lymphocytes are heated at a temperature of 42°C to 45°C for 10 minutes to 60 minutes to induce the heat shock proteins.

79. (New) The medication of Claim 55, wherein the lymphocytes are activated with the anti-CD3 antibody.

80. (New) The medication of Claim 55, wherein the lymphocytes are activated with IL-2.

81. (New) A method of producing the medication of Claim 55, comprising activating lymphocytes with anti-CD3 antibody and/or IL-2 and inducing heat shock proteins in the lymphocytes.

82. (New) The method of Claim 81, wherein the heat shock proteins are induced by heating the activated lymphocytes.

83. (New) The method of Claim 82, wherein the activated lymphocytes are heated in the presence of *Rauwolfia serpentine*.

84. (New) The method of Claim 82, wherein the activated lymphocytes are heated in the presence of reserpine.

85. (New) The method of Claim 81, wherein the lymphocytes are activated with the anti-CD3 antibody.

86. (New) The method of Claim 81, wherein the lymphocytes are activated with IL-2.

87. (New) A method of treating cancer, comprising administering an effective amount of the medication of Claim 55 to a subject in need thereof.

88. (New) The method of Claim 87, wherein *Rauwolfia serpentine* is also administered to the subject.

89. (New) The method of Claim 87, wherein reserpine is also administered to the subject.

90. (New) A method of treating a viral infection, comprising administering an effective amount of the medication of Claim 55 to a subject in need thereof.

91. (New) The method of Claim 90, wherein *Rauwolfia serpentine* is also administered to the subject.

92. (New) The method of Claim 90, wherein reserpine is also administered to the subject.

SUPPORT FOR THE AMENDMENTS

Newly-added Claims 55-92 are supported by the specification and the original claims. Accordingly, no new matter is believed to have been added to the present application by the amendments submitted above.